Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Metadata lists "Phio Pharmaceuticals Corp.", but the filing identifies "RXi Pharmaceuticals Corporation").
Filing Type: Form 8-K (Current Report).
Report Date: March 30, 2016.
Reporting Period: Quarter and fiscal year ended December 31, 2015.
Key Financial Metrics
The filing serves as a notification of the release of financial results but does not contain specific numerical data within the text provided. The actual figures for revenue, profit, cash flow, margins, debt, and liquidity are contained in the attached press release (Exhibit 99.1), which is not included in the source text. Therefore, the filing text does not provide a clear value for these metrics.
Material Changes
No specific material changes or comparative financial data are detailed in the body of this Form 8-K. The document solely references the reporting of results for the period ended December 31, 2015.
Guidance, Outlook, and Risks
Management Commentary: The report was signed by Geert Cauwenbergh, President, CEO, and acting CFO.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not treated as "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Outlook/Guidance: No specific forward-looking guidance or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the specific financial results (revenue, net loss, cash position) by reviewing the attached Press Release (Exhibit 99.1) referenced in the filing.
- Confirm the company name discrepancy between the metadata ("Phio Pharmaceuticals Corp.") and the filing ("RXi Pharmaceuticals Corporation").
- Review the full press release for any forward-looking statements or operational updates not captured in this summary.